Merck & Co
News/ News/ News/ Oncology/ R&D
Merck puts big bucks behind ADC alliance with China’s Kelun
Phil Taylor
antibody-drug conjugate, Kelun-Biotech, Merck & Co, Oncology, partnering
0 Comment
News/ News/ News/ News/ Oncology/ Patients/ R&D
Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial
Phil Taylor
cancer vaccine, immuno-oncology, melanoma, Merck & Co, Moderna, mRNA, mRNA vaccines, Oncology, personalisation
0 Comment
News/ News/ News/ Oncology/ R&D
GSK trumpets Jemperli vs Keytruda data in first-line NSCLC
Phil Taylor
GSK, immuno-oncology, Jemperli, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology
0 Comment
Cancer/ News/ News/ News/ Oncology/ Patients
AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign
Nicole Raleigh
AstraZeneca, campaign, early detection, Merck & Co, MSD, Never Miss, Oncology, Prostate cancer
0 Comment
Pharma M&A rumour mill grinds out Mirati’s name again
Phil Taylor
Amgen, KRAS, Lumakras, M&A, Merck & Co, Mirati
0 Comment
Market Access/ News/ News/ News/ News/ Oncology/ Patients
Opdivo backed by NICE for rare gastro-oesophageal cancers
Phil Taylor
Bristol-Myers Squibb, gastric cancer, HEOR, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo
0 Comment
News/ News/ News/ Oncology/ R&D
Merck bulks up in haematology, buying Imago for $1.35bn
Phil Taylor
bomedemstat, Haematology, Imago BioSciences, M&A, Merck & Co, Oncology
0 Comment
GSK, J&J, and AZ head this year’s access to medicines ranking
Phil Taylor
AbbVie, Access to Medicines Index, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, market access, Merck & Co
0 Comment